MorphoSys AG: MorphoSys Increases its 2013 Profit Guidance

          MorphoSys AG: MorphoSys Increases its 2013 Profit Guidance

MorphoSys AG / MorphoSys Increases its 2013 Profit Guidance . Ad hoc
announcement according to § 15 WpHG. Processed and transmitted by Thomson
Reuters ONE. The issuer is solely responsible for the content of this

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX OTC: MPSYY) today
increased its financial guidance for the current year. For the full-year 2013,
MorphoSys now expects an EBIT of EUR 7 million to EUR 10 million (up from
previously EUR 2 million to EUR 6 million) and revenues at the upper end of
the previously communicated guidance range of EUR 74 million to EUR 78
million. The change of the EBIT range is mainly driven by the positive revenue
development and lower than originally anticipated costs for the development of
the cancer program MOR202 under the co-development and cost-sharing agreement
with Celgene.
"The successful development of our proprietary portfolio and our partnered
programs is reflected in the strong financial performance this year. We
believe MorphoSys is well positioned and well-funded to broaden and advance
its proprietary development activities and to continue to build significant
value," stated Jens Holstein, Chief Financial Officer of MorphoSys AG.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys
is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates about MorphoSys, visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Media Release (PDF)


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / Munich Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press spacebar to pause and continue. Press esc to stop.